Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | Unmet needs in the polycythemia vera and essential thrombocythemia

David Ross • 1 Jun 2021
EHA 2021
Essential Thrombocythemia Myeloproliferative Neoplasms Polycythemia Vera Rare Diseases Bomedemstat Hydroxyurea Interferon Ruxolitinib

David Ross, MD, PhD, Royal Adelaide Hospital, Adelaide, Australia, Australia, talks on the most pressing unmet needs in the treatment of polycythemia vera and essential thrombocythemia, highlighting the small number of studies in these populations and low tolerance of toxicities. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

Disclosures

David Ross, MD, PhD, has received research funding and honoraria for lectures and advisory boards from Novartis and BMS/Celgene.

More from David Ross

3:18
Granulocytes & T-cells as biomarkers for relapse in CML following discontinuation of TKIs
David Ross • 8 Sep 2023
2:51
The genetic complexity of CML beyond BCR-ABL1 & the clinical impact of additional abnormalities
David Ross • 8 Sep 2023
2:05
ADORE: novel combinations with ruxolitinib for myelofibrosis
David Ross • 1 Jun 2021
1:47
Bomedemstat normalizes platelet count for essential thrombocythemia
David Ross • 1 Jun 2021

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals